Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
3.61
-0.53 (-12.74%)
Bozor ochiq: Aug 12, 2026, 11:45 AM EDT
3.92
-0.21 (-5.16%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Aptevo Therapeutics Inc., klinik tadqiqot va ishlab chiqish bosqichidagi biotexnologiya kompaniyasi, Amerika Qo'shma Shtatlarida turli xil saraton kasalliklarini davolash uchun immunoterapiya nomzodlarini ishlab chiqishga qaratilgan. Kompaniya ADAPTIR va ADAPTIR-FLEX platformalaridan foydalanib, saraton hujayralariga qarshi inson immunitetini kuchaytiradigan monospesifik, bispesifik va multispesifik antikor nomzodlarini yaratadi. Uning yetakchi klinik qon saratoni nomzodi mipletamig bo'lib, u o'tkir miyeloid leykemiyani davolash uchun 1b/2-bosqichli klinik sinovdan o'tmoqda. Kompaniya, shuningdek, ALG.APV-527ni ishlab chiqmoqda, bu esa malign plevral mezotelioma, mayda hujayrali o'pka, oshqozon/gastroezofageal, bosh va bo'yin skuamoz hujayrali karsinoma, oshqozon osti bezi, buyrak, tuxumdon, prostata, ko'krak bezi, bachadon bo'yni, yo'g'on ichak, bachadon shilliq qavati va siydik pufagi saratonini davolash uchun 1-bosqichli klinik sinovda bo'lgan yangi tadqiqot bispesifik ADAPTIR nomzodidir; APVO603, ko'plab qattiq o'smalarni davolash uchun preklinik gistamin agonisti bispesifik ADAPTIR nomzodi; APVO442, ko'plab qattiq o'smalarni davolash uchun ADAPTIR-FLEX platformasi texnologiyasiga asoslangan preklinik bispesifik nomzod; va APVO711, prostata saratonini davolash uchun preklinik qo'sh mexanizm bispesifik ADAPTIR nomzodi. U ALG.APV-527ni ishlab chiqish uchun Alligator Bioscience AB bilan hamkorlik va opsion shartnomasiga ega. Aptevo Therapeutics Inc. 2016-yilda ro'yxatga olingan va shtab-kvartirasi Sietl, Vashingtonda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Dirk Huebner M.D. | Senior Vice President & Chief Medical Officer |
| Mr. Jeffrey G. Lamothe CA | CEO, President & Director |
| Mr. Marvin L. White | Executive Chair |
| Ms. Daphne L. Taylor C.P.A. | Senior VP & CFO |
| Ms. Mary J. Janatpour Ph.D. | Senior VP & Chief Scientific Officer |
| Ms. Miriam Weber Miller | Vice President of Investor Relations & Corporate Communications |
| Ms. SoYoung Kwon J.D., LL.M. | Corporate Secretary, Senior VP, General Counsel, Business Development & Corporate Affairs |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-07-31 | DEF 14A | apvo-20260731.htm |
| 2026-07-31 | ARS | apvo-2026_-_annual_repor.pdf |
| 2026-07-27 | 8-K | apvo-20260727.htm |
| 2026-07-24 | S-8 | apvo-20260724.htm |
| 2026-06-30 | 8-K | apvo-20260629.htm |
| 2026-05-27 | 8-K | apvo-20260525.htm |
| 2026-05-13 | 8-K | apvo-20260513.htm |
| 2026-05-13 | 10-Q | apvo-20260331.htm |
| 2026-05-06 | 8-K | apvo-20260506.htm |
| 2026-03-26 | 8-K | apvo-20260326.htm |